274 related articles for article (PubMed ID: 33039577)
21. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.
Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
Osteoporos Int; 2005 Dec; 16(12):1883-93. PubMed ID: 16133649
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
Yoshizawa T; Nishino T; Okubo I; Yamazaki M
Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
25. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.
Li N; Zheng B; Liu M; Zhou H; Zhao L; Cai H; Huang J
Menopause; 2019 Aug; 26(8):906-914. PubMed ID: 30994577
[TBL] [Abstract][Full Text] [Related]
27. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
Stevenson M; Davis S; Lloyd-Jones M; Beverley C
Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
[TBL] [Abstract][Full Text] [Related]
28. Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population.
Walter E; Dellago H; Grillari J; Dimai HP; Hackl M
Bone; 2018 Mar; 108():44-54. PubMed ID: 29269173
[TBL] [Abstract][Full Text] [Related]
29. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
30. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
31. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
Honkanen LA; Mushlin AI; Lachs M; Schackman BR
J Am Geriatr Soc; 2006 Nov; 54(11):1658-65. PubMed ID: 17087691
[TBL] [Abstract][Full Text] [Related]
32. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years.
Reid IR; Horne AM; Mihov B; Bava U; Stewart A; Gamble GD
Lancet Diabetes Endocrinol; 2024 Apr; 12(4):247-256. PubMed ID: 38452783
[TBL] [Abstract][Full Text] [Related]
33. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
[No Abstract] [Full Text] [Related]
35. Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan.
Moriwaki K; Komaba H; Noto S; Yanagisawa S; Takiguchi T; Inoue H; Toujo T; Fukagawa M; Takahashi HE
J Bone Miner Res; 2013 Feb; 28(2):395-403. PubMed ID: 22991163
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of two inexpensive postfracture osteoporosis interventions: results of a randomized trial.
Majumdar SR; Lier DA; Leslie WD
J Clin Endocrinol Metab; 2013 May; 98(5):1991-2000. PubMed ID: 23596140
[TBL] [Abstract][Full Text] [Related]
37. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.
Ström O; Borgström F; Sen SS; Boonen S; Haentjens P; Johnell O; Kanis JA
Osteoporos Int; 2007 Aug; 18(8):1047-61. PubMed ID: 17333449
[TBL] [Abstract][Full Text] [Related]
39. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Reginster JY
Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
[TBL] [Abstract][Full Text] [Related]
40. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness.
Kerlikowske K; Salzmann P; Phillips KA; Cauley JA; Cummings SR
JAMA; 1999 Dec; 282(22):2156-63. PubMed ID: 10591338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
